Alzheimer’s Association Statement on Donanemab Phase 3 Topline Data Release

Overwhelming Bipartisan Support for Access to FDA-Approved Alzheimer’s Treatments on Display in Health Subcommittee Hearing

Recognizing AIM’s May Advocate of the Month: Priya Patel